Attached files

file filename
EX-32.1 - EXHIBIT 32.1 - UFP TECHNOLOGIES INCexh_321.htm
EX-31.2 - EXHIBIT 31.2 - UFP TECHNOLOGIES INCexh_312.htm
EX-31.1 - EXHIBIT 31.1 - UFP TECHNOLOGIES INCexh_311.htm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

 

(Mark one)

 

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended     SEPTEMBER 30, 2016    

 

OR

 

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ____ to ____

 

Commission File Number: 001-12648

 

UFP Technologies, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware 04-2314970
(State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.)

 

100 Hale Street, Newburyport, MA 01950, USA

(Address of principal executive offices) (Zip Code)

 

(978) 352-2200

(Registrant's telephone number, including area code)

 

_________________________________________

(Former name, former address, and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes X ;      No ____

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes   X ;      No ____

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

  Large accelerated filer  ☐
  Accelerated filer  ☒
  Non–accelerated filer  ☐ [Do not check if a smaller reporting company]
  Smaller reporting company    ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ____;    No X  

 

7,228,048 shares of registrant’s Common Stock, $0.01 par value, were outstanding as of November 2, 2016.

 

 

 

UFP Technologies, Inc.

 

Index

 

    Page
     
PART I - FINANCIAL INFORMATION 3
   
Item 1.   Financial Statements 3
     
Condensed Consolidated Balance Sheets as of September 30, 2016 (unaudited) and December 31, 2015 3
   
Condensed Consolidated Statements of Income for the Three and Nine Months Ended September 30, 2016 and September 30, 2015 (unaudited) 4
   
Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2016 and September 30, 2015 (unaudited) 5
   
Notes to Interim Condensed Consolidated Financial Statements 6
   
Item 2.    Management's Discussion and Analysis of Financial Condition and Results of Operations 12
     
Item 3.   Quantitative and Qualitative Disclosures about Market Risk 16
     
Item 4.   Controls and Procedures 16
     
PART II - OTHER INFORMATION 17
   
Item 1A. Risk Factors 17
     
Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds 17
     
Item 6. Exhibits 17
     
Signatures  18
   
Exhibit Index 18

 

 

2
 

PART I: FINANCIAL INFORMATION
ITEM 1:FINANCIAL STATEMENTS

 

UFP Technologies, Inc.

Condensed Consolidated Balance Sheets

(In thousands, except share data)

 

   September 30,
2016
  December 31,
2015
   (Unaudited)   
Assets         
Current assets:          
Cash and cash equivalents  $30,118   $29,804 
Receivables, less allowance for doubtful accounts of $597 at September 30, 2016 and $499 at December 31, 2015   22,307    17,481 
Inventories   14,568    14,202 
Prepaid expenses   2,161    930 
Refundable income taxes   481    1,186 
Total current assets   69,635    63,603 
Property, plant and equipment   96,390    90,564 
Less accumulated depreciation and amortization   (47,628)   (44,009)
Net property, plant and equipment   48,762    46,555 
Goodwill   7,322    7,322 
Intangible assets, net   397    636 
Other assets   1,927    1,834 
Total assets  $128,043   $119,950 
           
Liabilities and Stockholders’ Equity          
Current liabilities:          
Accounts payable  $5,106   $4,598 
Accrued expenses   5,372    5,374 
Current installments of long-term debt   1,028    1,011 
Total current liabilities   11,506    10,983 
Long-term debt, excluding current installments   84    859 
Deferred income taxes   3,107    2,883 
Other liabilities   1,858    1,653 
Total liabilities   16,555    16,378 
Commitments and contingencies          
Stockholders’ equity:          
Preferred stock, $.01 par value. Authorized 1,000,000 shares; zero shares issued or outstanding   -    - 
Common stock, $.01 par value. Authorized 20,000,000 shares; issued and outstanding 7,228,048 at September 30, 2016 and 7,170,377 at December 31, 2015   72    72 
Additional paid-in capital   25,142    23,705 
Retained earnings   86,861    80,382 
Treasury stock at cost - 29,559 at September 30, 2016 and December 31, 2015   (587)   (587)
Total stockholders’ equity   111,488    103,572 
Total liabilities and stockholders' equity  $128,043   $119,950 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

3
 

UFP Technologies, Inc.

Condensed Consolidated Statements of Income

(In thousands, except per share data)

(Unaudited)

 

   Three Months Ended  Nine Months Ended
   September 30,  September 30,
   2016  2015  2016  2015
Net sales  $37,220   $34,441   $109,626   $104,917 
Cost of sales   28,768    24,931    83,161    76,475 
Gross profit   8,452    9,510    26,465    28,442 
Selling, general & administrative expenses   6,027    5,604    18,402    18,404 
Restructuring costs   25    851    203    959 
Material overcharge settlement   (1,681)   -    (2,114)   - 
Gain on sale of fixed assets   -    -    (4)   (31)
Operating income   4,081    3,055    9,978    9,110 
Interest income (expense), net   25    9    51    (7)
Income before income tax expense   4,106    3,064    10,029    9,103 
Income tax expense   1,437    1,072    3,550    3,186 
Net income  $2,669   $1,992   $6,479   $5,917 
                     
Net income per share:                    
Basic  $0.37   $0.28   $0.90   $0.83 
Diluted  $0.37   $0.28   $0.89   $0.82 
Weighted average common shares outstanding:                    
Basic   7,225    7,131    7,213    7,108 
Diluted   7,312    7,230    7,294    7,212 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

4
 

UFP Technologies, Inc.

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

 

   Nine Months Ended
   September 30,
   2016  2015
Cash flows from operating activities:          
Net income  $6,479   $5,917 
Adjustments to reconcile net income to net cash provided by operating activities:          
Depreciation and amortization   4,109    3,507 
Gain on sale of fixed assets   (4)   (31)
Share-based compensation   871    873 
Excess tax benefit on share-based compensation   (126)   (219)
Deferred income taxes   224    283 
Changes in operating assets and liabilities:          
Receivables, net   (4,826)   (2,785)
Inventories   (366)   (642)
Prepaid expenses   (1,231)   (682)
Refundable income taxes   831    2,503 
Other assets   (93)   105 
Accounts payable   508    (666)
Accrued expenses   (2)   1,220 
Other liabilities   205    (136)
Net cash provided by operating activities   6,579    9,247 
Cash flows from investing activities:          
Additions to property, plant, and equipment   (6,077)   (13,003)
Proceeds from sale of fixed assets   4    31 
Net cash used in investing activities   (6,073)   (12,972)
Cash flows from financing activities:          
Principal repayments of long-term debt   (758)   (745)
Proceeds from exercise of stock options, net of attestation   529    220 
Excess tax benefit on share-based compensation   126    219 
Repurchases of common stock   -    (587)
Payment of statutory withholdings for stock options exercised and restricted stock units vested   (89)   (79)
Net cash used in financing activities   (192)   (972)
Net increase (decrease) in cash and cash equivalents   314    (4,697)
Cash and cash equivalents at beginning of period   29,804    34,052 
Cash and cash equivalents at end of period  $30,118   $29,355 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

5
 

Notes to Interim Condensed Consolidated Financial Statements

 

(1)Basis of Presentation

 

The interim condensed consolidated financial statements of UFP Technologies, Inc. (the “Company”) presented herein, have been prepared pursuant to the rules of the Securities and Exchange Commission for quarterly reports on Form 10-Q and do not include all the information and note disclosures required by accounting principles generally accepted in the United States of America. These statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2015, included in the Company's 2015 Annual Report on Form 10-K, as filed with the Securities and Exchange Commission.

 

The condensed consolidated balance sheet as of September 30, 2016, the condensed consolidated statements of income for the three- and nine-month periods ended September 30, 2016 and 2015, and the condensed consolidated statements of cash flows for the nine-month periods ended September 30, 2016 and 2015 are unaudited but, in the opinion of management, include all adjustments (consisting of normal, recurring adjustments) necessary for a fair presentation of results for these interim periods. The condensed consolidated balance sheet as of December 31, 2015 has been derived from the Company’s annual financial statements that were audited by an independent registered public accounting firm, but does not include all of the information and footnotes required for complete annual financial statements.

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.

 

The results of operations for the three- and nine-month periods ended September 30, 2016 are not necessarily indicative of the results to be expected for the entire fiscal year ending December 31, 2016.

 

Recent Accounting Pronouncements

 

In March 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-09, Improvements to Employee Share Based Payment Accounting. This ASU simplifies several aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards and classification on the statement of cash flows. The provisions of this ASU are effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. This amendment is applicable to the Company beginning in the first quarter of 2017. The Company is evaluating the impact of adopting this ASU on its consolidated financial position and results of operations.

 

(2)Supplemental Cash Flow Information

 

Cash paid (received) for interest and income taxes is as follows (in thousands):

 

   Nine Months Ended
   September 30,
   2016  2015
Interest, net  $(53)  $5 
Income taxes, net of refunds  $2,178   $400 

 

(3)Fair Value of Financial Instruments

 

The Company has financial instruments, such as accounts receivable, accounts payable, and accrued expenses, which are stated at carrying amounts that approximate fair value because of the short maturity of those instruments. The carrying amount of the Company’s long-term debt approximates fair value as the interest rate on the debt approximates the estimated borrowing rate currently available to the Company.

 

6
 

 

(4)Share-Based Compensation

 

Share-based compensation is measured at the grant date based on the fair value of the award and is recognized as an expense over the requisite service period (generally the vesting period of the equity grant).

 

The Company issues share-based awards through several plans that are described in detail in the notes to the consolidated financial statements for the year ended December 31, 2015. The compensation cost charged against income for those plans is included in selling, general & administrative expenses as follows (in thousands):

 

   Three Months Ended  Nine Months Ended
   September 30,  September 30,
   2016  2015  2016  2015
Total share-based compensation expense  $229   $226   $871   $873 

 

Share-based compensation for the nine-month periods ended September 30, 2016 and 2015 includes approximately $105,000, in each period respectively, representing the fair value of the Company’s common stock granted during the periods to the Company’s Board of Directors.

 

The total income tax benefit recognized in the condensed consolidated statements of income for share-based compensation arrangements was approximately $67,000 and $63,000, for the three-month periods ended September 30, 2016 and 2015, respectively, and $264,000 and $256,000, for the nine-month periods ended September 30, 2016 and 2015, respectively.

 

The following is a summary of stock option activity under all plans for the nine-month period ended September 30, 2016:

 

   Shares Under Options  Weighted Average Exercise Price
(per share)
  Weighted Average
Remaining
Contractual Life
(in years)
  Aggregate Intrinsic Value
(in thousands)
Outstanding at December 31, 2015   270,205   $15.40      
Granted   17,184    22.02        
Exercised   (44,887)   11.79           
Outstanding at September 30, 2016   242,502   $16.54    3.98   $2,415 
Exercisable at September 30, 2016   220,002   $16.05    4.18   $2,298 
Vested and expected to vest at September 30, 2016   242,502   $16.54    3.98   $2,415 

 

On June 9, 2016, the Company granted options to its directors for the purchase of 17,184 shares of common stock at that day’s closing price of $22.02. The compensation expense related to these grants was determined as the fair value of the options using the Black Scholes option pricing model based on the following assumptions:

 

Expected volatility   29.7%
Expected dividends   None 
Risk-free interest rate   0.9%
Exercise price  $22.02 
Expected term (years)   5.0 
Weighted average grant date fair value  $6.11 

 

The stock volatility for each grant is determined based on a review of the experience of the weighted average of historical daily price changes of the Company’s common stock over the expected option term, and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected term of the option. The expected term is calculated based on the simplified method.

 

7
 

During the nine-month periods ended September 30, 2016 and 2015, the total intrinsic value of all options exercised (i.e., the difference between the market price on the exercise date and the price paid by the employees to exercise the options) was approximately $564,000 and $989,000, respectively, and the total amount of consideration received by the Company from the exercised options was approximately $529,000 and $258,000, respectively. At its discretion, the Company allows option holders to surrender previously owned common stock in lieu of paying the exercise price and withholding taxes. During the nine months ended September 30, 2016, there were no shares surrendered for this purpose. During the nine months ended September 30, 2015, there were 1,632 shares surrendered at an average market price of $21.97.

 

During each of the three-month periods ended September 30, 2016 and 2015, the Company recognized compensation expense related to stock options granted to directors and employees of approximately $34,000 and $44,000, respectively. During each of the nine-month periods ended September 30, 2016 and 2015, the Company recognized compensation expense related to stock options granted to directors and employees of approximately $212,000 and $237,000, respectively.

 

On February 22, 2016, the Company’s Compensation Committee approved the award of $400,000, payable in shares of common stock to the Company’s Chairman, Chief Executive Officer, and President under the 2003 Incentive Plan. The shares will be issued on December 22, 2016. The Company recorded compensation expense associated with the award of $100,000 and $300,000, respectively, during the three- and nine-month periods ended September 30, 2016. The Company recorded compensation expense associated with a similar award of $100,000 and $300,000, respectively, during the three- and nine-month periods ended September 30, 2015.

 

The following table summarizes information about Restricted Stock Units (“RSUs”) activity during the nine-month period ended September 30, 2016:

 

   Restricted
Stock Units
  Weighted Average
Award Date
Fair Value
Unvested at December 31, 2015   40,645   $19.67 
Awarded   17,822    21.66 
Shares vested   (11,909)   20.94 
Unvested at September 30, 2016   46,558   $20.04 

 

During the three-month periods ended September 30, 2016 and 2015, the Company recorded compensation expense related to RSUs of approximately $95,000 and $82,000, respectively. During the nine-month periods ended September 30, 2016 and 2015, the Company recorded compensation expense related to RSUs of approximately $254,000 and $231,000, respectively.

 

At the Company’s discretion, RSU holders are given the option to net-share settle to cover the required minimum withholding tax, and the remaining amount is converted into the equivalent number of common shares. During the nine-month periods ended September 30, 2016 and 2015, 3,889 and 3,405 shares were surrendered at an average market price of $22.82 and $23.15, respectively.

 

As of September 30, 2016, the Company had approximately $947,000 of unrecognized compensation expense, which is expected to be recognized over a period of 3.5 years.

 

(5)Inventories

 

Inventories are stated at the lower of cost (first-in, first-out) or net realizable value, and consist of the following at the stated dates (in thousands):

 

8
 

 

   September 30,
2016
  December 31,
2015
Raw materials  $7,443   $7,506 
Work in process   1,367    1,192 
Finished goods   5,758    5,504 
Total inventory  $14,568   $14,202 

 

(6)Preferred Stock

 

On March 18, 2009, the Company declared a dividend of one preferred share purchase right (a “Right”) for each outstanding share of common stock, par value $0.01 per share, to the stockholders of record on March 20, 2009. Each Right entitles the registered holder to purchase from the Company one one-thousandth of a share of Series A Junior Participating Preferred Stock, par value $0.01 per share (the “Preferred Share”) of the Company, at a price of $25 per one one-thousandth of a Preferred Share subject to adjustment and the terms of the Rights Agreement. The Rights expire on March 19, 2019.

 

(7)Income Per Share

 

Basic income per share is based on the weighted average number of shares of common stock outstanding. Diluted income per share is based upon the weighted average number of common shares outstanding and dilutive common stock equivalent shares outstanding during each period.

 

The weighted average number of shares used to compute basic and diluted net income per share consisted of the following (in thousands):

 

   Three Months Ended  Nine Months Ended
   September 30,  September 30,
   2016  2015  2016  2015
Weighted average common shares outstanding, basic   7,225    7,131    7,213    7,108 
Weighted average common equivalent shares due to stock options and RSUs   87    99    81    104 
Weighted average common shares outstanding, diluted   7,312    7,230    7,294    7,212 

 

The computation of diluted earnings per share excludes the effect of the potential exercise of stock awards, including stock options, when the average market price of the common stock is lower than the exercise price of the related options during the period. These outstanding stock awards are not included in the computation of diluted income per share because the effect would be antidilutive. For the three-month periods ended September 30, 2016 and 2015, the number of stock awards excluded from the computation of diluted earnings per share for this reason was 35,193 and 65,193, respectively. For the nine-month periods ended September 30, 2016 and 2015, the number of stock awards excluded from the computation of diluted earnings per share for this reason was 52,377 and 82,719, respectively.

 

(8)Segment Reporting

 

The Company consists of a single operating and reportable segment.

 

Revenues from customers outside of the United States are not material. No customer comprised more than 10% of the Company’s consolidated revenues for the three- and nine-month periods ended September 30, 2016. All of the Company’s assets are located in the United States.

 

The Company’s products are primarily sold to customers within the Medical, Automotive, Consumer, Electronics, Industrial, and Aerospace and Defense markets. Net sales by market for the three- and nine-month periods ended September 30, 2016 and 2015 are as follows (in thousands):

 

9
 

 

   Three Months Ended September 30,  Nine Months Ended September 30,
   2016  2015  2016  2015
Market  Net Sales  %  Net Sales  %  Net Sales  %  Net Sales  %
                         
Medical  $16,492    44.3%  $13,809    40.1%  $48,931    44.6%  $42,595    40.6%
Automotive   6,944    18.7%   6,258    18.2%   20,718    18.9%   21,193    20.2%
Consumer   5,580    15.0%   4,710    13.7%   15,171    13.8%   12,385    11.8%
Electronics   2,992    8.0%   3,427    10.0%   9,055    8.3%   10,538    10.0%
Industrial   2,802    7.5%   2,856    8.3%   8,281    7.6%   8,120    7.7%
Aerospace & Defense   2,410    6.5%   3,381    9.8%   7,470    6.8%   10,086    9.6%
Net Sales  $37,220    100.0%  $34,441    100.0%  $109,626    100.0%  $104,917    100.0%

 

Note – certain amounts for the three- and nine-months ended September 30, 2015 were reclassified between markets to conform to the current period presentation.

 

(9)Other Intangible Assets

 

The carrying values of the Company’s definite lived intangible assets as of September 30, 2016 and December 31, 2015, are as follows (in thousands):

 

   Patents  Non-
Compete
  Customer
List
  Total
Estimated useful life  14 years  5 years  5 years   
Gross amount at September 30, 2016  $429   $512   $2,046   $2,987 
Accumulated amortization at September 30, 2016   (429)   (434)   (1,727)   (2,590)
Net balance at September 30, 2016  $-   $78   $319   $397 
                     
Gross amount at December 31, 2015  $429   $512   $2,046   $2,987 
Accumulated amortization at December 31, 2015   (429)   (387)   (1,535)   (2,351)
Net balance at December 31, 2015  $-   $125   $511   $636 

 

Amortization expense related to intangible assets was approximately $79,000 for each of the three- month periods ended September 30, 2016 and 2015, and approximately $238,000 for each of the nine-month periods ended September 30, 2016 and 2015. The estimated remaining amortization expense as of September 30, 2016 is as follows (in thousands):

 

Remainder of:   
2016   79 
2017   318 
Total  $397 

 

(10)Income Taxes

 

The income tax expense included in the accompanying unaudited condensed consolidated statements of income principally relates to the Company’s proportionate share of the pre-tax income of its wholly-owned subsidiaries. The determination of income tax expense for interim reporting purposes is based upon the estimated effective tax rate for the year, adjusted for the impact of any discrete items which are accounted for in the period in which they occur.

 

The Company recorded tax expense of approximately 35% of income before income tax expense for each of the three-month periods ended September 30, 2016 and 2015. The Company recorded tax expense of approximately 35.4% and 35% of income before income tax expense for the nine-month periods ended September 30, 2016 and 2015, respectively. The increase in the effective tax rate for the nine-month period ended September 30, 2016 is due to a tax assessment of approximately $40,000 from one jurisdiction recorded in the first quarter of 2016.

 

10
 

 

(11)Plant Consolidations

 

Restructuring Costs

 

On March 18, 2015, the Company committed to move forward with a plan to cease operations at its Raritan, New Jersey, plant and consolidate operations into its Newburyport, Massachusetts, facility and other UFP facilities. The Company’s decision was in response to a continued decline in business at the Raritan facility and the recent purchase of the 137,000-square-foot facility in Newburyport. The activities related to this consolidation were substantially complete at December 31, 2015.

 

The Company also relocated all operations of its Haverhill, Massachusetts, and Byfield, Massachusetts facilities and plans to relocate certain operations of its Georgetown, Massachusetts facility to Newburyport. The Haverhill and Byfield relocations were complete at December 31, 2015, and the Georgetown relocation is substantially complete.

 

The Company expects to incur approximately $2.1 million in one-time expenses in connection with the Massachusetts consolidations. Included in this amount are approximately $180,000 relating to employee severance payments and relocation costs, approximately $1.5 million in moving expenses and expenses associated with vacating the Raritan, Haverhill, and Byfield properties, and approximately $360,000 in lease termination costs. Total cash charges are estimated at $2.0 million. The Company expects annual cost savings of approximately $1.0 million as a result of these consolidations. Through September 30, 2016, the Company had incurred approximately $1.9 million of the costs for this restructuring plan.

 

The company recorded the following restructuring costs associated with the Massachusetts consolidations for the three- and nine-month periods ended September 30, 2016 and 2015 (in thousands):

 

   Three Months Ended  Nine Months Ended
Restructuring Costs - Massachusetts  September 30,  September 30,
   2016  2015  2016  2015
Employee severance  $-   $204   $-   $204 
Relocation   25    286    203    310 
Lease termination   -    361    -    361 
Total  $25   $851   $203   $875 

 

On July 16, 2014, the Company committed to move forward with a plan to cease operations at its Costa Mesa, California, plant and consolidate operations into its Rancho Dominguez, California, facility and other UFP facilities. The Company’s decision was in response to the December 31, 2014, expiration of the lease on the Costa Mesa facility as well as the close proximity of the two properties. The California consolidation is complete.

 

The company recorded the following restructuring costs associated with the California consolidation for the three- and nine-month periods ended September 30, 2016 and 2015 (in thousands):

 

   Three Months Ended  Nine Months Ended
   September 30,  September 30,
Restructuring Costs - California  2016  2015  2016  2015
Employee severance  $-   $-   $-   $18 
Relocation   -    -    -    66 
Total  $-   $-   $-   $84 

 

Costs for 2016 were reclassified in the Condensed Consolidated Statement of Income as “Restructuring Costs” from Cost of Sales. Costs for the three months ended September 30, 2015 were reclassified in the Condensed Consolidated Statement of Income as “Restructuring Costs” from Cost of Sales. Costs for the nine months ended September 30, 2015 were reclassified in the Condensed Consolidated Statement of Income as “Restructuring Costs” as follows: $941,000 from Cost of Sales and $18,000 from General and Administrative expenses:

 

11
 

 

(12)Related Party Transactions

 

Daniel Croteau, who has been a member of the Company’s board of directors since December 16, 2015, is the Chief Executive Officer of Vention Medical, Inc., a customer of the Company. Sales to Vention for the nine-months ended September 30, 2016 were approximately $403,000. Open accounts receivable from Vention were approximately $66,000 at September 30, 2016.

 

(13)Material Overcharge Settlement

 

The Company was a participant in a class action lawsuit against a number of polyurethane foam suppliers (“Defendants”) that recently reached settlement. The suit was filed to recover damages and obtain injunctive relief for Defendants’ alleged violations of the federal antitrust laws with respect to the fixing of prices of polyurethane foam sold from January 1, 1999 through August 2010. The Company recorded gains of approximately $1.7 million and $2.1 million during the three- and nine-month periods ended September 30, 2016, respectively, which represents the full settlement amount received. The settlement amount is recorded as “Material overcharge settlement” in the operating income section of the Condensed Consolidated Statements of Income.

 

 

ITEM 2: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Forward-looking Statements

 

Some of the statements contained in this Report are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”). These statements are subject to known and unknown risks, uncertainties, and other factors, which may cause our or our industry’s actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about the Company’s prospects, anticipated trends in the different markets in which the Company competes, including the medical, automotive, consumer, electronics, industrial and aerospace and defense markets, anticipated new customer contracts, statements regarding anticipated advantages relating to the Company’s decisions to consolidate its facilities and the expected cost savings and efficiencies associated therewith, anticipated advantages and the timing associated with requalification of parts, anticipated advantages of maintaining fewer, larger plants, anticipated advantages the Company expects to realize from its investments and capital expenditures, including the development of and investments in its molded fiber product lines, expectations regarding the manufacturing capacity and efficiencies of the Company and the expected timing associated therewith, statements about the Company’s acquisition opportunities and strategies, its participation and growth in multiple markets, its business opportunities, the Company’s growth potential and strategies for growth, anticipated revenues and the timing of such revenues, and any indication that the Company may be able to sustain or increase its sales and earnings or sales and earnings growth rates. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation risks and uncertainties associated with the identification of suitable acquisition candidates and the successful, efficient execution of acquisition transactions and integration of any such acquisition candidates, risks and uncertainties associated with plant closures and consolidations and expected efficiencies from consolidating manufacturing, risks and uncertainties associated with the requalification of parts, the risk that we may not be able to finalize anticipated new customer contracts, risks associated with the implementation of new production equipment and requalification or recertification of transferred equipment in a timely, cost-efficient manner, and risks that any benefits from such new equipment may be delayed or not fully realized, or that the Company may be unable to fully utilize its expected production capacity. Accordingly, actual results may differ materially.

 

12
 

In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “potential,” and similar expressions intended to identify forward-looking statements. Our actual results could be different from the results described in or anticipated by our forward-looking statements due to the inherent uncertainty of estimates, forecasts, and projections, and may be materially better or worse than anticipated. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Forward-looking statements represent our estimates and assumptions only as of the date of this Report. We expressly disclaim any duty to provide updates to forward-looking statements, and the estimates and assumptions associated with them, after the date of this Report, in order to reflect changes in circumstances or expectations, or the occurrence of unanticipated events, except to the extent required by applicable securities laws. All of the forward-looking statements are qualified in their entirety by reference to the factors discussed above and under “Risk Factors” set forth in Part I Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, as well as the risks and uncertainties discussed elsewhere in this Report. We qualify all of our forward-looking statements by these cautionary statements. We caution you that these risks are not exhaustive. We operate in a continually changing business environment and new risks emerge from time to time.

 

Unless the context requires otherwise, the terms “we”, “us”, “our”, or “the Company” refer to UFP Technologies, Inc. and its consolidated subsidiaries.

 

Overview

 

UFP Technologies is an innovative designer and custom converter of foams, plastics, composites, and natural fiber products, principally serving the medical, automotive, consumer, electronics, industrial, and aerospace and defense markets. The Company consists of a single operating and reportable segment.

 

Strong third quarter growth in sales to customers in the medical, consumer and automotive markets were partially offset by weakness in demand from customers in the military and electronics markets. The Company anticipates continued growth in sales to customers in the medical market. Continued manufacturing inefficiencies resulting from recent plant consolidations and the resulting need to requalify parts with many of the Company’s customers in the medical market caused an increase in material and labor costs that negatively impacted gross margins. The Company anticipates that these increases will be temporary and that gross margins will improve as new employees get trained and parts get requalified.

 

The Company’s current strategy includes organic growth and growth through strategic acquisitions.

 

Results of Operations

 

Sales

 

Sales for the three-month period ended September 30, 2016 increased approximately 8.1% to $37.2 million from sales of $34.4 million for the same period in 2015. The increase in sales for the three-month period ended September 30, 2016 was primarily a result of increases in sales to customers in the medical, consumer and automotive markets of approximately 19.4%, 18.5% and 11.0%, respectively, partially offset by decreases in sales to customers in the aerospace & defense and electronics markets of approximately 28.7% and 12.7%, respectively. The increase in sales to customers in the medical market was largely due to a new five-year contract with one of the Company’s larger customers in this market as well as an overall increase in demand from other medical customers. The increase in sales to customers in the consumer market was largely due to increased demand for molded fiber protective packaging for consumer products. The increase in sales to customers in the automotive market was primarily due to increased demand for interior trim parts from a customer in the southeast, resulting from the customer resolving certain production issues. The reduction in sales to customers in the aerospace and defense market was largely due to continued cuts in government spending. The decrease in sales to customers in the electronics market was primarily due to a temporary spike in demand for packaging at one of our larger customers in 2015.

 

Sales for the nine-month period ended September 30, 2016 increased approximately 4.5% to $109.6 million from sales of $104.9 million for the same period in 2015. The increase in sales for the nine-month period ended September 30, 2016 was primarily a result of increases in sales to customers in the medical and consumer markets of approximately 14.9% and 22.9%, respectively, partially offset by decreases in sales to customers in the aerospace & defense and consumer markets of approximately 25.9% and 14.1%, respectively. The increase in sales to customers in the medical market was largely due to a new five-year contract with one of the Company’s larger customers in this market as well as an overall increase in demand from other medical customers. The increase in sales to customers in the consumer market was largely due to increased demand for molded fiber protective packaging for consumer products. The reduction in sales to customers in the aerospace and defense market was largely due to continued cuts in government spending. The decrease in sales to customers in the electronics market was primarily due to general softness in demand for protective packaging.

 

13
 

Gross Profit

 

Gross profit as a percentage of sales (“gross margin”) decreased to 22.7% for the three-month period ended September 30, 2016, from 27.6% for the same period in 2015. As a percentage of sales, material and labor costs collectively increased 2.9%, while overhead increased 2.0%. The increase in collective material and labor costs as a percentage of sales is primarily due to manufacturing inefficiencies resulting from recent plant consolidations and the resulting need to requalify parts with many of the Company’s customers in the medical market. The increase in overhead is primarily due to an increase in indirect labor costs of approximately $635,000 due largely to temporary hires to assist in the requalification of parts, an increase in plant and equipment maintenance costs of approximately $365,000 due largely to one-time costs associated with the plant consolidations and an increase in depreciation of approximately $164,000 due largely to depreciation on the Company’s new building in Newburyport.

 

Gross profit as a percentage of sales decreased to 24.1% for the nine-month period ended September 30, 2016, from 27.1% for the same period in 2015. As a percentage of sales, material and labor costs collectively increased 2.4%, while overhead increased 0.6%. The increase in collective material and labor costs as a percentage of sales is primarily due to manufacturing inefficiencies resulting from recent plant consolidations and the resulting need to requalify parts with many of the Company’s customers in the medical market, as well as a non-recurring write-off of approximately $288,000 in obsolete tooling and inventory.

 

Selling, General and Administrative Expenses

 

Selling, general, and administrative expenses (“SG&A”) increased approximately 7.5% to $6.0 million for the three-month period ended September 30, 2016, from $5.6 million for the same period in 2015. As a percentage of sales, SG&A decreased to 16.2% for the three-month period ended September 30, 2016, from 16.3% for the same three-month period in 2015. The increase in SG&A for the three-month period ended September 30, 2016, is primarily due to one-time consulting and recruiting costs associated with filling open positions and company-wide training. The decrease in SG&A as a percentage of sales for the three-month period ended September 30, 2016, is largely due to the leveraging of relatively fixed SG&A expenses against the increase in sales.

 

Selling, general, and administrative expenses (“SG&A”) was unchanged at $18.4 million for the nine-month period ended September 30, 2016, as compared to the same nine-month period in 2015. As a percentage of sales, SG&A decreased to 16.8% for the nine-month period ended September 30, 2016, from 17.5% for the same nine-month period in 2015. The decrease in SG&A as a percentage of sales for the nine-month period ended September 30, 2016, is largely due to the leveraging of relatively fixed SG&A expenses against the increase in sales.

 

Restructuring Costs

 

For the three-month period ended September 30, 2016, the Company incurred restructuring costs of approximately $25,000, compared to approximately $851,000 for the same period in 2015.

 

For the nine-month period ended September 30, 2016, the Company incurred restructuring costs of approximately $203,000, compared to approximately $1.0 million for the same period in 2015.

 

Additional information regarding restructuring costs can be found in Note 11 of the Notes to Interim Condensed Consolidated Financial Statements.

 

Material Overcharge Settlement

 

The Company was a participant in a class action lawsuit against a number of polyurethane foam suppliers (“Defendants”) that recently reached settlement. The suit was filed to recover damages and obtain injunctive relief for Defendants’ alleged violations of the federal antitrust laws with respect to the fixing of prices of polyurethane foam sold from January 1, 1999 through August 2010. The Company recorded gains of approximately $1.7 million and $2.1 million during the three- and nine-month periods ended September 30, 2016, respectively, which represents the full settlement amount received. The settlement amount is recorded as “Material overcharge settlement” in the operating income section of the Condensed Consolidated Statements of Income.

 

14
 

Interest Income and Expense

 

The Company had net interest income of approximately $25,000 and $9,000 for the three-month periods ended September 30, 2016 and 2015, respectively. The Company had net interest income of approximately $51,000 and net interest expense of approximately $7,000 for the nine-month periods ended September 30, 2016 and 2015, respectively. The increase in net interest income is primarily due to an increase in interest earned on money market accounts and certificates of deposit and decreasing interest costs on the Company’s term loans.

 

Income Taxes

 

The Company’s effective tax rate was approximately 35.0% for each of the three-month periods ended September 30, 2016 and 2015. The Company’s effective tax rate was approximately 35.4% and 35.0% for the nine-month periods ended September 30, 2016 and 2015, respectively. The increase in the effective tax rate for the nine-month period ended September 30, 2016 is due to a tax assessment of approximately $40,000 from one jurisdiction recorded in the first quarter of 2016. The Company has deferred tax assets on its books associated with net operating losses generated in previous years. The Company has considered both positive and negative available evidence in its determination that the deferred tax assets are more likely than not to be realized, and has not recorded a tax valuation allowance at September 30, 2016. The Company will continue to assess whether the deferred tax assets will be realizable and, when appropriate, will record a valuation allowance against these assets. The amount of the net deferred tax asset considered realizable, however, could be reduced in the near term if estimates of future taxable income during the carry-forward period are reduced.

 

Liquidity and Capital Resources

 

The Company generally funds its operating expenses, capital requirements, and growth plan through internally generated cash and bank credit facilities.

 

Cash Flows

 

Net cash provided by operations for the nine-month period ended September 30, 2016 was approximately $6.6 million and was primarily a result of net income generated of $6.5 million, depreciation and amortization of approximately $4.1 million, share-based compensation of $0.9 million, an increase in deferred taxes of $0.2 million, an increase in accounts payable of approximately $0.5 million due to the timing of vendor payments in the ordinary course of business and a decrease in refundable income taxes of approximately $0.8 million. These cash inflows and adjustments to income were partially offset by an increase in accounts receivable of approximately $4.8 million due in part to strong September sales, an increase in prepaid expenses of approximately $1.2 million due to upfront insurance premium payments and an increase in inventories of approximately $0.4 million.

 

Net cash used in investing activities during the nine-month period ended September 30, 2016 was approximately $6.1 million and was primarily the result of additions of manufacturing machinery and equipment and the renovations of the new manufacturing and headquarters building in Massachusetts.

 

Net cash used in financing activities was approximately $192,000 during the nine-month period ended September 30, 2016, representing cash used to service term debt of approximately $758,000 and to pay statutory withholding for stock options exercised and restricted stock units vested of approximately $89,000, largely offset by excess tax benefits on share-based compensation of approximately $126,000 and net proceeds received upon stock options exercises of approximately $529,000.

 

Outstanding and Available Debt

 

The Company maintains an unsecured $40 million revolving credit facility with Bank of America, N.A. The credit facility calls for interest of LIBOR plus a margin that ranges from 1.0% to 1.5% or, at the discretion of the Company, the bank’s prime rate less a margin that ranges from 0.25% to zero. In both cases the applicable margin is dependent upon Company performance. Under the credit facility, the Company is subject to a minimum fixed-charge coverage financial covenant as well as a maximum total funded debt to EBITDA financial covenant. The Company’s $40 million credit facility matures on November 30, 2018.

 

As of September 30, 2016, the Company had no borrowings outstanding under the credit facility and the Company was in compliance with all covenants under the credit facility.

 

15
 

In 2012, the Company financed the purchase of two molded fiber machines through five-year term loans that mature in September 2017. The annual interest rate is fixed at 1.83% and the loans are secured by the related molded fiber machines. As of September 30, 2016, the outstanding balance of the term loan facility was approximately $1.1 million.

 

Future Liquidity

 

The Company requires cash to pay its operating expenses, purchase capital equipment, and to service its contractual obligations. The Company’s principal sources of funds are its operations and its revolving credit facility. The Company generated cash of approximately $6.6 million from operations during the nine-month period ended September 30, 2016; however, the Company cannot guarantee that its operations will generate cash in future periods. The Company’s longer-term liquidity is contingent upon future operating performance.

 

Throughout fiscal 2016, the Company plans to continue to add capacity to enhance operating efficiencies in its manufacturing plants. The Company may also further expand its Newburyport, Massachusetts, manufacturing plant. The Company may consider additional acquisitions of companies, technologies, or products that are complementary to its business. The Company believes that its existing resources, including its revolving credit facility, together with cash expected to be generated from operations and funds expected to be available to it through any necessary equipment financings and additional bank borrowings, will be sufficient to fund its cash flow requirements, including capital asset acquisitions, through the next twelve months.

 

Stock Repurchase Program

 

On June 16, 2015, the Company announced that its Board of Directors authorized the repurchase of up to $10.0 million of the Company’s outstanding common stock. Under the program, the Company is authorized to repurchase shares through Rule 10b5-1 plans, open market purchases, privately negotiated transactions, block purchases or otherwise in accordance with applicable federal securities laws, including Rule 10b-18 of the Securities Exchange Act of 1934. The stock repurchase program will end upon the earlier of the date on which the plan is terminated by the Board or when all authorized repurchases are completed. The timing and amount of stock repurchases, if any, will be determined based upon our evaluation of market conditions and other factors. The stock repurchase program may be suspended, modified or discontinued at any time, and the Company has no obligation to repurchase any amount of its common stock under the program. The Company did not repurchase any shares of its common stock under this program in the first nine months of 2016. Through September 30, 2016, the Company had repurchased a total of 29,559 shares of its common stock under this program at a cost of approximately $587,000. At September 30, 2016, approximately $9.4 million was available for future repurchases of the Company’s common stock under this authorization.

 

Commitments and Contractual Obligations

 

There have been no material changes outside the ordinary course of business to our contractual obligations and commitments, as disclosed in our Annual Report on Form 10-K for the year ended December 31, 2015.

 

Off-Balance-Sheet Arrangements

 

The Company had no off-balance-sheet arrangements during the nine-month period ended September 30, 2016, other than operating leases.

 

ITEM 3: QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

There have been no material changes in our market risks as previously disclosed in Item 7A of our Annual Report on Form 10-K for the year ended December 31, 2015.

 

ITEM 4: CONTROLS AND PROCEDURES

 

As of the end of the period covered by this report (the “Evaluation Date”), the Company’s management, under the supervision and with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, performed an evaluation of the effectiveness of the design and operation of the Company’s “disclosure controls and procedures” (as defined in SEC Rule 13a-15(e) or 15d-15(e)). Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of the Evaluation Date, the Company’s disclosure controls and procedures were effective to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act of 1934, as amended, is (i) recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and (ii) accumulated and communicated to the Company’s management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

 

16
 

There has been no change in the Company’s internal control over financial reporting during the most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

 

PART II: OTHER INFORMATION

 

ITEM 1A: RISK FACTORS

 

There have been no material changes from the risk factors previously disclosed in Part 1 - Item 1A of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015.

 

ITEM 2: UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

Issuer’s Purchases of Equity Securities

 

On June 16, 2015, the Company issued a press release announcing that its Board of Directors authorized the repurchase of up to $10.0 million of the Company’s outstanding common stock. The Company did not repurchase any shares of its common stock under this program in the first nine months of 2016. Through September 30, 2016, the Company had repurchased a total of 29,559 shares of its common stock under this program at a cost of approximately $587,000. At September 30, 2016, approximately $9.4 million was available for future repurchases of the Company's common stock under this authorization.

 

ITEM 6: EXHIBITS

 

Exhibit No. Description
31.1 Rule 13a-14(a)/15d-14(a) Certification of the Chief Executive Officer.*
31.2 Rule 13a-14(a)/15d-14(a) Certification of the Chief Financial Officer.*
32.1 Certifications pursuant to 18 U.S.C., Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**
101.INS XBRL Instance Document.*
101.SCH XBRL Taxonomy Extension Schema Document.*
101.CAL XBRL Taxonomy Calculation Linkbase Document.*
101.LAB XBRL Taxonomy Label Linkbase Document.*
101.PRE XBRL Taxonomy Presentation Linkbase Document.*
101.DEF XBRL Taxonomy Extension Definition Linkbase Document.*

__________________

* Filed herewith.  
**  Furnished herewith.  

 

17
 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

UFP TECHNOLOGIES, INC.

 

Date: November 9, 2016   By:    /s/ R. Jeffrey Bailly
   

R. Jeffrey Bailly

Chairman, Chief Executive Officer,
President, and Director

(Principal Executive Officer)

     
  Date: November 9, 2016   By:    /s/ Ronald J. Lataille 
   

Ronald J. Lataille

Chief Financial Officer

(Principal Financial Officer)

 

 

 

EXHIBIT INDEX

 

Exhibit No. Description
31.1 Rule 13a-14(a)/15d-14(a) Certification of the Chief Executive Officer.*
31.2 Rule 13a-14(a)/15d-14(a) Certification of the Chief Financial Officer.*
32.1 Certifications pursuant to 18 U.S.C., Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**
101.INS XBRL Instance Document.*
101.SCH XBRL Taxonomy Extension Schema Document.*
101.CAL XBRL Taxonomy Calculation Linkbase Document.*
101.LAB XBRL Taxonomy Label Linkbase Document.*
101.PRE XBRL Taxonomy Presentation Linkbase Document.*
101.DEF XBRL Taxonomy Extension Definition Linkbase Document.*

__________________

* Filed herewith.  
**  Furnished herewith.  

 

 

18